Developer docs
API playgroundTry for free, no card

Search company profiles

Pepgen

Full company profile

uuid000027o

Namestring
Pepgen
Legal namestring
PepGen, Inc.
Websiteurl
pepgen.com
Company typeenum
Public
Founded yearint
2021
Descriptiontext

PepGen is a clinical-stage biotechnology company developing a new generation of disease-modifying oligonucleotide therapies for serious genetic neuromuscular and neurological diseases, with no approved products and no commercial revenue. The company's core technology is its proprietary Enhanced Delivery Oligonucleotide (EDO) platform — engineered cell-penetrating peptides conjugated to therapeutic oligonucleotides — designed to overcome the historic delivery challenge of efficiently reaching skeletal muscle, cardiac muscle, and nerve cells while maintaining minimal immunogenicity and robust stability. Composition-of-matter patent protection extends into the second half of 2042.

PepGen's lead clinical asset is PGN-EDODM1 for myotonic dystrophy type 1 (DM1), a rare disease affecting over 115,000 people in the U.S. and EU with no approved disease-modifying therapy. PGN-EDODM1 has demonstrated the highest single-dose splicing correction rates ever reported in DM1 and is being evaluated in the FREEDOM-DM1 Phase 1 and FREEDOM2-DM1 Phase 2 trials; it holds both FDA Orphan Drug and Fast Track Designations. The company's second program, PGN-EDO51, targets exon 51 skipping for Duchenne muscular dystrophy (DMD) and is in CONNECT1-EDO51 and CONNECT2-EDO51 Phase 2 studies. Clinical trial enrollment spans the U.S., U.K., Canada, South Korea, Australia, and New Zealand.

The company's business model is R&D-driven and pre-commercial: revenue is non-existent, capital is raised through equity financings (cumulative disclosed funding of approximately $354M+ across rounds including $112.5M in 2021, $80.1M in February 2024, and roughly $115M in September 2025), and cash burn is substantial with a $89.7M FY2025 net loss. Customers are defined as patient populations (DM1 and DMD amenable to exon 51 skipping), with go-to-market limited to clinical trial sites today and no disclosed commercial pricing, partnership royalties, or licensing revenue. Key risks include the March 2026 FDA partial clinical hold on FREEDOM2-DM1, mixed Phase 2 functional data at the 5 mg/kg dose, and an 18% share price decline tied to the hold.

Short descriptiontext

PepGen is a clinical-stage biotechnology company developing proprietary Enhanced Delivery Oligonucleotide (EDO) peptide-conjugated therapies for genetic neuromuscular diseases, with lead programs PGN-EDODM1 for myotonic dystrophy type 1 and PGN-EDO51 for Duchenne muscular dystrophy, both currently in Phase 2 trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oligonucleotide therapeutics, neuromuscular disease treatments, peptide-conjugated drugs, genetic medicine delivery, rare disease therapies
Industry3 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
Social media profiles3 records
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

PepGen is a clinical-stage biotechnology company developing a pipeline of investigational, disease-modifying oligonucleotide therapeutics for serious genetic neuromuscular and neurological diseases. Its lead product candidate, PGN-EDODM1, targets myotonic dystrophy type 1 (DM1), while PGN-EDO51 targets Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The company's differentiating foundation is its proprietary Enhanced Delivery Oligonucleotide (EDO) peptide platform, which conjugates engineered cell-penetrating peptides to oligonucleotide cargoes to enable delivery to skeletal and cardiac muscle and nerve cells.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Highest rates of splicing correction ever reported after a single dose in DM1 patients
+1 more record
Product overview1 text field

PepGen is a clinical-stage biotechnology company advancing a new generation of oligonucleotide therapies using its Enhanced Delivery Oligonucleotide (EDO) platform. The company's lead product is PGN-EDODM1 for myotonic dystrophy type 1 (DM1), currently in Phase 1 (FREEDOM-DM1) and Phase 2 (FREEDOM2-DM1) clinical trials. The company also has PGN-EDO51 for Duchenne muscular dystrophy in Phase 2 development. The EDO platform technology enables efficient delivery of therapeutic oligonucleotide cargoes into affected tissues and cells, overcoming key challenges of previous generations of therapies.

Product and service2 records
1PGN-EDODM1
CategoryInvestigational oligonucleotide therapy
Description

A novel peptide-conjugated oligonucleotide candidate being studied in patients with myotonic dystrophy type 1 (DM1), a rare genetic neuromuscular disease with no approved disease-modifying therapies. It has demonstrated the highest rates of splicing correction ever reported after a single dose and is generally well tolerated in clinical trials.

2PGN-EDO51
CategoryInvestigational oligonucleotide therapy
Description

An Enhanced Delivery Oligonucleotide candidate targeting exon 51 skipping for Duchenne muscular dystrophy (DMD), being evaluated in Phase 2 CONNECT1-EDO51 and CONNECT2-EDO51 clinical studies for patients amenable to exon 51 skipping.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sarepta is the leading commercial-stage developer of exon-skipping therapies for Duchenne muscular dystrophy (e.g., Exondys 51, Vyondys 53, Elevidys). PepGen directly competes with Sarepta in DMD exon 51 skipping with PGN-EDO51 and in the broader neuromuscular oligonucleotide space.

TypeDirect peer
Description

Dyne is developing oligonucleotide-based therapies (e.g., DYNE-101 for DM1, DYNE-251 for DMD exon 51) using antibody-targeted conjugates for muscle delivery. It is the most direct head-to-head competitor to PepGen's EDO platform in both DM1 and DMD.

TypeDirect peer
Description

Avidity uses antibody-RNA conjugates (AOCs) to deliver oligonucleotides to muscle, including DM1 (del-zota) and DMD programs. Its muscle-targeted delivery approach competes directly with PepGen's EDO platform for the same patient populations.

TypeDirect peer
Description

Wave is a clinical-stage oligonucleotide platform company developing RNA-targeted therapies for rare and neurological diseases, including DM1 and DMD programs. It is comparable to PepGen as an oligonucleotide platform competitor in the same disease areas.

TypeBroad incumbent
Description

Ionis is the established leader in antisense oligonucleotide (ASO) technology and a key partner/licensor in the oligonucleotide field. Its broad neuromuscular and neurological pipeline (e.g., Spinraza for SMA) makes it a relevant incumbent peer to PepGen's targeted delivery platform.

TypeBroad incumbent
Description

Alnylam is the established RNAi therapeutics leader (Onpattro, Givlaari, Amvuttra) with growing CNS and rare-disease pipeline. Its Board Chair Laurie Keating was formerly Alnylam's EVP/GC, and Alnylam is a natural strategic acquirer in the oligonucleotide delivery space where PepGen competes.

TypeEmerging player
Description

Solid is developing gene therapies and oligonucleotide candidates for Duchenne muscular dystrophy. It is comparable to PepGen as a DMD-focused emerging biotech competing for similar exon-skipping and disease-modifying patient outcomes.

TypeEmerging player
Description

Edgewise develops muscle-targeted therapeutics for rare neuromuscular diseases including Duchenne and Becker muscular dystrophy. Its muscle biology focus and small-molecule approach provide adjacent competition to PepGen's oligonucleotide-based muscle delivery.

TypeEmerging player
Description

Scholar Rock develops therapeutics targeting growth factor signaling (e.g., apitegromab for SMA, SRK-015-class molecules) in neuromuscular diseases. Its regulatory and clinical leadership (e.g., Hayley Parker, Lisa Wyman) directly overlaps with PepGen's neuromuscular focus.

TypeEmerging player
Description

Capricor develops cell therapy and exosome-based therapeutics (e.g., deramiocel for DMD) for rare neuromuscular diseases. It is an emerging player targeting the same DMD patient population as PepGen's PGN-EDO51 program.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles29 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pepgen

Biopharmaceuticalspepgen.com

PepGen is a clinical-stage biotechnology company developing proprietary Enhanced Delivery Oligonucleotide (EDO) peptide-conjugated therapies for genetic neuromuscular diseases, with lead programs PGN-EDODM1 for myotonic dystrophy type 1 and PGN-EDO51 for Duchenne muscular dystrophy, both currently in Phase 2 trials.

What Pepgen does

PepGen is a clinical-stage biotechnology company developing a new generation of disease-modifying oligonucleotide therapies for serious genetic neuromuscular and neurological diseases, with no approved products and no commercial revenue. The company's core technology is its proprietary Enhanced Delivery Oligonucleotide (EDO) platform — engineered cell-penetrating peptides conjugated to therapeutic oligonucleotides — designed to overcome the historic delivery challenge of efficiently reaching skeletal muscle, cardiac muscle, and nerve cells while maintaining minimal immunogenicity and robust stability. Composition-of-matter patent protection extends into the second half of 2042.

PepGen's lead clinical asset is PGN-EDODM1 for myotonic dystrophy type 1 (DM1), a rare disease affecting over 115,000 people in the U.S. and EU with no approved disease-modifying therapy. PGN-EDODM1 has demonstrated the highest single-dose splicing correction rates ever reported in DM1 and is being evaluated in the FREEDOM-DM1 Phase 1 and FREEDOM2-DM1 Phase 2 trials; it holds both FDA Orphan Drug and Fast Track Designations. The company's second program, PGN-EDO51, targets exon 51 skipping for Duchenne muscular dystrophy (DMD) and is in CONNECT1-EDO51 and CONNECT2-EDO51 Phase 2 studies. Clinical trial enrollment spans the U.S., U.K., Canada, South Korea, Australia, and New Zealand.

The company's business model is R&D-driven and pre-commercial: revenue is non-existent, capital is raised through equity financings (cumulative disclosed funding of approximately $354M+ across rounds including $112.5M in 2021, $80.1M in February 2024, and roughly $115M in September 2025), and cash burn is substantial with a $89.7M FY2025 net loss. Customers are defined as patient populations (DM1 and DMD amenable to exon 51 skipping), with go-to-market limited to clinical trial sites today and no disclosed commercial pricing, partnership royalties, or licensing revenue. Key risks include the March 2026 FDA partial clinical hold on FREEDOM2-DM1, mixed Phase 2 functional data at the 5 mg/kg dose, and an 18% share price decline tied to the hold.

Pepgen firmographics

Firmographics
Name
Pepgen
Legal name
PepGen, Inc.
Website
https://pepgen.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
PepGen is a clinical-stage biotechnology company developing proprietary Enhanced Delivery Oligonucleotide (EDO) peptide-conjugated therapies for genetic neuromuscular diseases, with lead programs PGN-EDODM1 for myotonic dystrophy type 1 and PGN-EDO51 for Duchenne muscular dystrophy, both currently in Phase 2 trials.
Ownership category
akta.pro rank

Pepgen industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Oligonucleotide therapeutics
  • Neuromuscular disease treatments
  • Peptide-conjugated drugs
  • Genetic medicine delivery
  • Rare disease therapies

Where Pepgen is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Pepgen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Distribution channels1 record

Marketing channels4 records

Pepgen product offering

Product offering

Core offering

PepGen is a clinical-stage biotechnology company developing a pipeline of investigational, disease-modifying oligonucleotide therapeutics for serious genetic neuromuscular and neurological diseases. Its lead product candidate, PGN-EDODM1, targets myotonic dystrophy type 1 (DM1), while PGN-EDO51 targets Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The company's differentiating foundation is its proprietary Enhanced Delivery Oligonucleotide (EDO) peptide platform, which conjugates engineered cell-penetrating peptides to oligonucleotide cargoes to enable delivery to skeletal and cardiac muscle and nerve cells.

Product overview

PepGen is a clinical-stage biotechnology company advancing a new generation of oligonucleotide therapies using its Enhanced Delivery Oligonucleotide (EDO) platform. The company's lead product is PGN-EDODM1 for myotonic dystrophy type 1 (DM1), currently in Phase 1 (FREEDOM-DM1) and Phase 2 (FREEDOM2-DM1) clinical trials. The company also has PGN-EDO51 for Duchenne muscular dystrophy in Phase 2 development. The EDO platform technology enables efficient delivery of therapeutic oligonucleotide cargoes into affected tissues and cells, overcoming key challenges of previous generations of therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • PGN-EDODM1 A novel peptide-conjugated oligonucleotide candidate being studied in patients with myotonic dystrophy type 1 (DM1), a rare genetic neuromuscular disease with no approved disease-modifying therapies. It has demonstrated the highest rates of splicing correction ever reported after a single dose and is generally well tolerated in clinical trials.
  • PGN-EDO51 An Enhanced Delivery Oligonucleotide candidate targeting exon 51 skipping for Duchenne muscular dystrophy (DMD), being evaluated in Phase 2 CONNECT1-EDO51 and CONNECT2-EDO51 clinical studies for patients amenable to exon 51 skipping.

Quantifiable outcome

  • Highest rates of splicing correction ever reported after a single dose in DM1 patients
  • +1 more outcomes

Companies that use Pepgen

Customer profile

Segments2 records

Ideal customer profiles3 records

Pepgen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Pepgen partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Pepgen competitors and assessment

Company assessment

Direct peers

  • Sarepta Therapeutics: Sarepta is the leading commercial-stage developer of exon-skipping therapies for Duchenne muscular dystrophy (e.g., Exondys 51, Vyondys 53, Elevidys). PepGen directly competes with Sarepta in DMD exon 51 skipping with PGN-EDO51 and in the broader neuromuscular oligonucleotide space.
  • Dyne Therapeutics: Dyne is developing oligonucleotide-based therapies (e.g., DYNE-101 for DM1, DYNE-251 for DMD exon 51) using antibody-targeted conjugates for muscle delivery. It is the most direct head-to-head competitor to PepGen's EDO platform in both DM1 and DMD.
  • Avidity Biosciences: Avidity uses antibody-RNA conjugates (AOCs) to deliver oligonucleotides to muscle, including DM1 (del-zota) and DMD programs. Its muscle-targeted delivery approach competes directly with PepGen's EDO platform for the same patient populations.
  • Wave Life Sciences: Wave is a clinical-stage oligonucleotide platform company developing RNA-targeted therapies for rare and neurological diseases, including DM1 and DMD programs. It is comparable to PepGen as an oligonucleotide platform competitor in the same disease areas.

Broad incumbents

  • Ionis Pharmaceuticals: Ionis is the established leader in antisense oligonucleotide (ASO) technology and a key partner/licensor in the oligonucleotide field. Its broad neuromuscular and neurological pipeline (e.g., Spinraza for SMA) makes it a relevant incumbent peer to PepGen's targeted delivery platform.
  • Alnylam Pharmaceuticals: Alnylam is the established RNAi therapeutics leader (Onpattro, Givlaari, Amvuttra) with growing CNS and rare-disease pipeline. Its Board Chair Laurie Keating was formerly Alnylam's EVP/GC, and Alnylam is a natural strategic acquirer in the oligonucleotide delivery space where PepGen competes.

Emerging players

  • Solid Biosciences: Solid is developing gene therapies and oligonucleotide candidates for Duchenne muscular dystrophy. It is comparable to PepGen as a DMD-focused emerging biotech competing for similar exon-skipping and disease-modifying patient outcomes.
  • Edgewise Therapeutics: Edgewise develops muscle-targeted therapeutics for rare neuromuscular diseases including Duchenne and Becker muscular dystrophy. Its muscle biology focus and small-molecule approach provide adjacent competition to PepGen's oligonucleotide-based muscle delivery.
  • Scholar Rock: Scholar Rock develops therapeutics targeting growth factor signaling (e.g., apitegromab for SMA, SRK-015-class molecules) in neuromuscular diseases. Its regulatory and clinical leadership (e.g., Hayley Parker, Lisa Wyman) directly overlaps with PepGen's neuromuscular focus.
  • Capricor Therapeutics: Capricor develops cell therapy and exosome-based therapeutics (e.g., deramiocel for DMD) for rare neuromuscular diseases. It is an emerging player targeting the same DMD patient population as PepGen's PGN-EDO51 program.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Pepgen social profiles

Digital presence

Pepgen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pepgen leadership team

Management profile

Number of profiles

Profiles29 records

Pepgen funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pepgen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pepgen

What does Pepgen do?

PepGen is a clinical-stage biotechnology company developing a pipeline of investigational, disease-modifying oligonucleotide therapeutics for serious genetic neuromuscular and neurological diseases. Its lead product candidate, PGN-EDODM1, targets myotonic dystrophy type 1 (DM1), while PGN-EDO51 targets Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The company's differentiating foundation is its proprietary Enhanced Delivery Oligonucleotide (EDO) peptide platform, which conjugates engineered cell-penetrating peptides to oligonucleotide cargoes to enable delivery to skeletal and cardiac muscle and nerve cells.

Is Pepgen a public or private company?

Pepgen is a public company. It is classified as public and is currently operating.

When was Pepgen founded?

Pepgen was founded in 2021. It employs 51 to 100 people.

Where is Pepgen based?

Pepgen is headquartered in Boston, United States, in the North America region.

Who are Pepgen's main competitors?

Direct peers on record are Sarepta Therapeutics, Dyne Therapeutics, Avidity Biosciences and Wave Life Sciences. Broad incumbents are Ionis Pharmaceuticals and Alnylam Pharmaceuticals. Emerging players are Solid Biosciences, Edgewise Therapeutics, Scholar Rock and Capricor Therapeutics.

Does Pepgen have an API?

No public API is recorded for Pepgen.

What industry is Pepgen in?

Pepgen's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewPepGen Inc. Stock 12‑Month Price Target Raised to $14, Implies 221% UpsideAnalysts' average price target for PepGen Inc. rose to $14 from $13.75, implying about 221% upside from the Nov. 13 close. The consensus remains Buy across 7 analysts, with 6 Buys, 1 Hold, and 0 Sells.Pulse 2.0PepGen: $125 Million Public Offering To Fund Clinical DevelopmentPepGen priced a public offering of 25 million shares at $5 each, raising $125 million before expenses. The company will use proceeds for clinical development of its myotonic dystrophy treatment PGN-EDODM1, following positive Phase 2 results. The offering is expected to close on November 13.TradingViewPepGen prices $125M public offering at $5 per sharePepGen priced a $125M public offering of 25M shares at $5 per share, with underwriters having a 30-day option to buy up to 3.75M additional shares. The offering is expected to close on November 13, 2026, and net proceeds will fund clinical development and working capital. The stock rose about 1.7% after hours.Pulse 2.0PepGen: Positive Phase 2 Data Support Higher-Dose Study As Cash Reaches $104.8 MillionPepGen reported positive Phase 2 data from its 10 mg/kg cohort of PGN-EDODM1 for myotonic dystrophy type 1, with mean splicing correction of 46.5%. The company ended Q3 2026 with $104.8 million in cash and investments. An independent board recommended advancing to a 12.5 mg/kg cohort, with results expected in H1 2027.TradingViewPepGen (PEPG) Prices $125M Offering at $5.00 per SharePepGen priced 25 million shares at $5.00 each, expecting gross proceeds of $125 million before offering costs. Underwriters have a 30-day option to buy up to 3.75 million additional shares, and closing is expected on or about November 13, 2026. Proceeds will fund clinical development and working capital.Seeking AlphaPepGen: Stock Soars On DM1 Data, But Caution Warranted On Small Sample Sizes (NASDAQ:PEPG)PepGen Inc. stock surged over 100% on trading yesterday and rose more than 20% in early trading today, buoyed by new data on its DM1 drug. The company's stock is trading at $5.26, up 14.10% from the previous close. The article cautions that the data comes from small sample sizes.BioSpacePepGen shares almost double as DM1 oligonucleotide achieves ‘best in class’ splicingPepGen's PGN-EDODM1 oligonucleotide achieved 46.5% mean splicing correction in a Phase 2 trial for myotonic dystrophy type 1, outperforming competitors. The stock rose 92% to $4.61, and a higher dose arm is fully enrolled with results expected in the first half of 2027.MarketScreenerHealth Care Up on Defensive Rotation - Health Care RoundupHealth-care stocks rose as traders rotated into defensive sectors amid AI-boom concerns. PepGen shares surged after promising trial results for a neuromuscular treatment, while Oura agreed to buy Counsel Health for $625 million. Hims & Hers shares fell after narrowing its sales outlook due to higher third-quarter costs.MarketWatchHealth Care Up on Defensive Rotation - Health Care RoundupHealth-care stocks rose as traders rotated into defensive sectors amid AI boom concerns. PepGen shares surged after promising trial results for a neuromuscular treatment, while Oura agreed to buy Counsel Health for $625 million. Hims & Hers shares fell after narrowing its sales outlook due to higher third-quarter costs.BioPharma DivePepGen soars on promising early data for muscular dystrophy drugPepGen's drug PGN-EDODM1 showed 46.5% average splicing correction in a Phase 2 trial for myotonic dystrophy type 1, sending shares up over 90%. The company reported the highest splicing correction ever for a DM1 drug, with no cumulative kidney damage. PepGen plans to report higher-dose results in the first half of next year.